Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.72 |
| ▸ | FYN | P06241 | 9/20 | 0.66 |
| ▸ | TNF | P01375 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485751 | 0.82 | FYN (0.67) | KCNH2FYN | |
| SCHEMBL20485758 | 0.81 | FYN (0.73) | FYN | |
| SCHEMBL20486271 | 0.80 | FYN (0.62) | KCNH2FYN | |
| SCHEMBL20485794 | 0.80 | FYN (0.74) | FYN | |
| SCHEMBL18613370 | 0.79 | FYN (1.00) | KCNH2FYN | |
| SCHEMBL18613402 | 0.77 | FYN (1.00) | KCNH2FYN | |
| SCHEMBL20485662 | 0.76 | FYN (0.76) | FYN | |
| SCHEMBL16332051 | 0.76 | FYN (0.79) | KCNH2FYN | |
| SCHEMBL20485734 | 0.75 | FYN (0.69) | FYN | |
| SCHEMBL20486161 | 0.75 | FYN (0.73) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | KCNH2 1949/4885FYN 1/4885TNF 4154/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | KCNH2 1949/4885FYN 1/4885TNF 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.